Arjona Ferreira Juan Camilo 4

4 · Organon & Co. · Filed Apr 2, 2025

Form 4

Period: 2025-03-31

Head of R&D & CMO

Transactions

Award
Stock Option (right to buy)
2025-03-31+198,019→ 198,019 total
Exercise: $14.89→ Common Stock (198,019 underlying)
Exercise/Conversion
Restricted Stock Units
2025-03-31−8,865→ 17,730 total
→ Common Stock (8,865 underlying)
Tax Payment
Common Stock
2025-03-31$14.51/sh−3,172$46,026→ 17,380.355 total
Exercise/Conversion
Common Stock
2025-03-31+8,865→ 20,552.355 total
Award
Restricted Stock Units
2025-03-31+40,295→ 40,295 total
→ Common Stock (40,295 underlying)

Footnotes (5)

[F1]This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
[F2]Each RSU converts into one share of Organon common stock.
[F3]The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
[F4]The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
[F5]On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

Documents

1 file